Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aztreonam + teicoplanin
- Development stage
- Preclinical
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
A combination antibiotic regimen consisting of aztreonam, a monobactam antibiotic effective against gram-negative bacteria, and teicoplanin, a glycopeptide antibiotic effective against gram-positive bacteria. This combination provides broad-spectrum antimicrobial coverage. Aztreonam inhibits bacterial cell wall synthesis by binding to penicillin binding protein 3 (PBP3), while teicoplanin inhibits peptidoglycan polymerization. The combination has been studied for treating infections in immunocompromised patients, particularly those with leukemia and septicemia.
02
Targets
Beyond the preview
Go deeper on aztreonam + teicoplanin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aztreonam + teicoplanin.